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Abstract Although rare, renal replacement therapy (RRT)
for the treatment of the metabolic, respiratory and hemo-
dynamic complications of intoxications may be required.
Understanding the natural clearance of the medications
along with their volume of distribution, protein binding and
molecular weight will help in understanding the benefit of
commencing RRT. This information will aid in choosing
the optimal forms of RRT in an urgent setting. Overdose
of common pediatric medications are discussed with
suggestions on the type of RRT within this educational
review.
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Introduction
Accidental and intentional intoxications occur in about 7.5
million cases per year, resulting in approximately 10,000
deaths per year in the USA [1]. Data from the Toxic
Exposure Surveillance System of the American Association
of Poison Centers identify that 65% of these intoxications
occur in people less than 20 years of age, yet this age group
only accounts for 11% of the fatalities. While the number of
children with toxic ingestions is very small, these patients
are ill enough to require therapy in the intensive care unit
(ICU) due to respiratory, metabolic or cardiac compromise
[2]. Holubek et al. reported a trend in the changes of the
etiology of intoxications as well as of therapy between the
years 1985 and 2005, noting that more than 19,000 cases of
intoxication required extracorporeal therapy as a treatment
[3]. They also noted that there was a change in both the
etiology (an increase in anti-convulsant overdose) and the
therapy [a trend away from charcoal hemoperfusion (CH)]
for these intoxications.
The management for toxic ingestions has changed over
time. In the early mid 1980s and early 1990s, CH was
commonly used as a therapy for intoxications [4]. New
forms of renal replacement therapy (RRT), including high-
flux hemodialysis (HD) and continuous renal replacement
therapy (CRRT) have, for the most part, replaced the use of
CH [5]. Additionally, in the last decade, a number of
specific rescue therapies have been developed for the
treatment of some intoxications, avoiding the need for
RRT [6]. Examples of these include naloxone for opiate
or narcotic overdose, n-acetylcysteine for the treatment
of acetaminophen intoxication and fomepizole as the
specific treatment for alcohol intoxications [7–10].
Despite these advances in rescue therapy, a significant
number of adults and children continue to require RRT as
an adjunct to their native renal function for removal of the
drug [11].
This review will describe common intoxications in the
pediatric age group and their therapeutic intervention with
RRT.
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When the pediatric patient presents for the care of a toxic
ingestion, it is important to determine the natural elimina-
tion process, i.e. whether the toxic substance is hepatically
or renally excreted. If a medication is excreted via the renal
system in the setting of concomitant kidney injury, the half-
life of that medication will be prolonged and, therefore,
RRT may be indicated [1, 11].
Currently available data have yet to identify an absolute
indication or the best RRT mode to treat intoxications [12].
It is suggested that RRT should be used in the case of
worsening metabolic consequences, including metabolic
acidosis and lactic acidosis, with or without concomitant
hypertension. Further respiratory depression related to a
direct central nervous system (CNS) effect of the medica-
tion or cardiac dysrhythmias may occur secondary to direct
cardiac toxicity. RRT should be considered in the setting of
impairment with underlying organ dysfunction and in the
face of worsening metabolic and respiratory compromise.
In addition, the basic level of medical care needs to be done
as indicated (e.g. saline diuresis, enteral charcoal placement
or gastric lavage if there is an adequate airway protection)
[1, 6].
Extracorporeal therapy modalities to support the elimi-
nation of intoxications would include RRT, peritoneal
dialysis, CH, HD (both standard as well as high flux) as
well as CRRT [5, 11].
Peritoneal dialysis
Peritoneal dialysis (PD) has been used in the past as a
treatment modality for acute intoxications [13]. PD can be
performed for acute intoxications as it is used in the settings
of acute kidney injury (AKI) or end-stage kidney disease
(ESRD). The mechanism of toxic clearance in PD is by
diffusion, and the factors that affect clearance include
volume and frequency of exchanges of the PD solution and
the concentration of the intoxicant present in the serum.
The advantages of using PD as a continuous form of RRT
are (1) its relative simplicity, (2) availability, (3) avoidance
of anticoagulation and (4) lower cost compared to other
RRT treatment modalities. The disadvantage (using urea
as a marker of clearance) is that compared to HD or
CRRT, PD is the least effective model of elimination
[14]. Small molecular weight medications (i.e. lithium)
can be eliminated by PD, but due to the greater clearance
that HD and CRRT offer in general, PD should be used
only when other options for RRT are not available or
feasible [15].
Charcoal hemoperfusion
With the diminished availability of CH cartridges as well as
a decreasing expertise among health professionals with
using these membranes, CH treatment has become less
common. CH was commonly used in the past as a way to
bind protein-bound intoxicants. The use of CH membranes
is associated with hypothermia, hemodynamic compromise,
coagulation abnormalities and thrombocytopenia and
hypocalcemia [16]. CH was often coupled with HD in line
to negate some of the side effects. The difficulty of
performing sequential CH with hemodialysis is the large
extracorporeal volume that would be necessary to use these
in tandem. It would not be unusual that a 400- to 500-mL
extracorporeal circuit would be needed to support both
systems in sequence. The cost of keeping a “ready to go”
CH cartridge available with a relatively short shelf life and
a reduction in the manufacturing of these cartridges have
resulted in the decreased use of this method [5].
Hemodialysis
Hemodialysis comes in standard as well as high-efficiency
or high-flux modalities, both of which use clearance by
diffusion. The major difference is the pore size of the
membrane, the type of membrane and the amount of
dialysate flow that occurs. Typically, with flux or high-
efficiency HD, membranes with a larger pore size (as large
as 20 kDa) are available for the clearance of intoxications.
With the advent of high-flux or high-efficiency HD
membranes, the use of CH has essentially become
something of the past [17].
Continuous renal replacement therapy
The use of CRRT has become commonplace in pediatric
ICU settings during the last decade and a half [18]. CRRT
either in a convective mode by effecting mass transport of
the medication across the membrane or in a diffusive mode
is often used in patients with AKI. Studies using sieving
coefficients have clearly demonstrated that there is a higher
clearance of larger molecular weight molecules and higher
protein membrane mediations when convective clearance is
used [19]. Therefore, if CRRT is to be used for intoxica-
tions, the focus should be predominantly on a convective
modality. A large disadvantage of CRRT for intoxications is
that it is less efficient and the patient has less mobility as
compared to HD [12].
If intoxicants have a large volume of distribution, HD
can be used to remove the initial intravascular load of this
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rebound that would occur as HD is discontinued.
Single-pass albumin dialysis/molecular absorbent
regenerating system
In the last decade, the use of single-pass albumin dialysis
and a molecular absorbent regenerating system has been
reported for hepatic dysfunction. These are essentially a
CRRT circuit with an additional albumin-based dialysate
circuit that allows for protein-bound molecules to transfer
from the patient’s blood into the protein of the dialysate
[20]. These systems can be used for protein-bound
intoxicants, but they are not readily available at most
institutions. Single-pass albumin dialysis has the additional
cost of the albumin. No comparison data evaluating
clearance by these new treatment modalities to high flux
HD are available. There are also a number of case reports
on the use of these therapies [21–23].
Extracorporeal membrane oxygenation
In the case of poor patient hemodynamics and a patient at
extremis, then extracorporeal support with venous arterial
extracorporeal membrane oxygenation (ECMO) may be
necessary to support the patient hemodynamically [24].
Once stable, RRT can be added to the ECMO circuit for
elimination of the intoxicant
Treatment of intoxications: decision issues
Before beginning RRT for a toxic ingestion, the following
issues about that intoxication need to be considered:
1. Was it delivered as a short or prolonged release
product?
2. What is the volume of distribution?
3. What is the molecular weight?
4. What is it protein binding?
The medication half-life needs to be characterized. If the
patient has been overdosed with a sustained release
product, there will be an ongoing slow delivery of
medications into the plasma space with subsequent com-
plications. This is where the use of gastro-intestinal (GI)
elimination in addition to RRT may be necessary.
If RRT is being considered, the molecular weight,
protein binding and volume of distribution of the toxin
will need to be accounted for. Large molecular weight
medications are less well cleared by RRT. Medications that
have a high protein binding are also removed less
efficiently by RRT. Finally, in medications with a large
volume of distribution through multiple compartments of
the body, RRT will only clear what is in the plasma space,
so the elimination of the intoxicant will be prolonged.
Management of specific toxic medication ingestions
Table 1 identifies common medications that are still
c a u s e so fi n t o x i c a t i o ni nc h i l d r e nt o g e t h e rw i t ht h e i r
molecular weight, volume of distribution and protein-
bound percentages.
Vancomycin
Vancomycin is a commonly used medication for the
treatment of Gram-positive infections. It has a large
molecular weight and relatively large volume of distribu-
tion, and it is highly protein bound. Vancomycin essentially
acts as a double compartment system with an intravascular
and extravascular component, respectively. Historically,
CH was the treatment for vancomycin intoxication as
vancomycin was thought not to be well removed by RRT.
Drug Molecular weight (Da) Volume of distribution (L/kg) % protein bound
Vancomycin 1500 0.2-1.25 75
Gentamicin 477 0.25-0.3 0
Lithium 6.9 0.6-0.9 0
Aspirin 138 0.17 90
Theophylline 180 0.45-0.7 60
Carbamazepine 236 0.8-1.8 78
Valproic acid 144 0.1-0.2 90
Metformin 166 0.5 0
Methotrexate 454 Acute use 0.18 50
Chronic use 0.4-0.8
Table 1 Characteristics of
common drugs which may
require renal replacement
therapy in intoxication
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has been found to successfully decrease acute vancomycin
levels [25, 26]. It is possible to wait for the tissue levels to
pass into the vascular space and upon rebound, repeat the
HD procedure. Alternatively, sequential therapy of HD
followed by convective clearance with high-flow CRRT
(as a way to prevent secondary rebound and for elimination)
may be used.
Aminoglycosides
Aminoglycosides are also commonly used antibiotics for
the treatment of Gram-negative infections. In contrast to
vancomycin, they have a lower molecular weight and lower
volume of distribution and are minimally protein bound.
These medications are easily cleared by both standard as
well as high-dose HD. If prolonged therapy RRT is
necessary, high-volume hemofiltration (preferably in con-
vective mode) for ongoing elimination of this medication
may be used [27].
Lithium
Lithium is a relatively common medication seen in both
accidental and purposeful overdoses. Lithium can occur
both as an acute intoxication in patients naïve to this
medication or an acute intoxication in a patient on the
medication chronically. The latter setting results in higher
saturation of the medication, resulting in both the natural
decay and RRT clearance taking longer as compared to the
patient naïve to the medication. This thought process is
important in determining the degree of time needed for
elimination. Lithium has a relatively small molecular
weight, a medium to large volume of distribution and low
protein binding. Many clinical series have shown that
lithium is easily removed with standard or high-flux HD.
It has been further shown that the volume distribution is
a little larger than that of other medications. In the case
of an overdose of extended-release lithium, the sequential
use of HD followed by hemofiltration will allow for
ongoing elimination of lithium, preventing the rebound
effect [28–30].
Aspirin
Aspirin overdose has continued to be common, primarily in
the adolescent suicidal population [31]. It has a relatively
small molecular weight and small volume of distribution,
but it is highly protein bound. Aspirin has been shown to be
eliminated very easily with high-efficiency HD, with the aim
ofavoidingthe metabolic consequencesofthe CNS aswellas
the metabolic consequences of aspirin overdose [32].
Theophylline
Theophylline is a medication that is being used less and
less. Historically, theophylline was only cleared with the
use of CH. Because of its relatively small molecular weight,
medium to higher level of volume of distribution and
mild to high protein binding, CH was preferred with this
medication. With the use of high-efficiency HD, theophyl-
line can be easily cleared. A prolonged release of a long-
acting form of theophylline may necessitate HD followed
by CRRT for ongoing elimination [33].
Carbamazepine
Carbamazepine is a common medication used for seizures.
Carbamazepine intoxication, like lithium intoxications, can
occur in an acute or acute on chronic setting. Relative to
other medications, carbamazepine has a relatively large
volume of distribution and is highly protein bound, yet
the molecular weight is relatively small. Historically,
carbamazepine was thought to be cleared only by CH
[34]. However, high-flux HD can clear carbamazepine
very easily despite the high protein binding and the high
volume of distribution [35]. The use of serial HD therapies
or sequential HD followed by CRRT may be necessary.
Recent work by Askenazi et al. noted that albumin added
to the dialysate solution during diffusive CRRT enhanced
the clearance of carbamazepine as opposed to albumin-
free dialysate [36].
Valproic acid
Valproic acid is also another highly protein-bound anticon-
vulsant [37]. Both the volume of distribution and the
molecular weight are smaller than carbamazepine [38].
Valproic acid can be eliminated with the use of high-flux
HD followed, if necessary, by CRRT [39–41]. Similar to
Askenazi et al. [36], Churchwell et al. regarded albumin-
treated dialysate as a way to absorb the valproic acid onto
the protein for enhanced elimination. This approach enables
CRRT to be used in the case of a hemodynamically
compromised patient, but it does add to the overall cost of
care [42].
Metformin
Metformin use is becoming more common as the obesity
rate in the USA goes up. Metformin intoxication in some
patients can cause an acute lactic acidosis [43]. Metformin
is eliminated naturally through the GI tract, is poorly
protein bound and has a mild volume of distribution.
Metformin overdose can be treated easily with standard or
538 Pediatr Nephrol (2011) 26:535–541high-flux HD as a way to correct the lactic acidosis as well
as to remove the medication [44].
Methotrexate
Methotrexate has been associated with AKI in approxi-
mately 1.8% of patients treated in osteosarcoma trials [45].
The clinical symptoms include gastrointestinal distress,
hepatic insufficiency, AKI and bone marrow suppression.
Like many of the other medications described herein, the
natural clearance will be diminished in the face of hepatic
or renal impairment. The volume of distribution is affected
by whether or not methotrexate is being given as a initial or
chronic therapy. In the setting of a chronic therapy the
volume of distribution is larger, making the elimination of
the medication longer to occur. If RRT is needed, high-flux
HD remains the optimal form of clearance compared to
other forms of RRT [46]. In the setting of chronic treatment
and AKI, clearance may occur over weeks [47].
Important teaching points
As opposed to the setting of AKI, if dialysis is needed to
treat an acute intoxication, the dialysate or replacement
bath needs to have the therapeutic levels of phosphorous
and potassium in order to avoid electrolyte disturbances
[48].
Summary
Renal replacement therapy is not commonly utilized for
treating intoxications in children, and CH, once a common
procedure, has essentially been relegated to the past.
Despite the perception of poor clearance, many medications
that are highly protein bound can be removed through the
use of high-flux or high-efficiency HD membranes. Many
medication intoxications have a volume of distribution such
that a rebound may occur once RRT is removed. If this is
the case, serial HD treatments or the use of sequential
HD followed by CRRT may be performed until the
medication is naturally eliminated. Peritoneal dialysis has
a role in RRT and can be considered if other options are
not available.
High-flux or high-efficiency HD should always be
considered the first line of treatment if the patient tolerates
this therapy. High-flux or high-efficiency HD followed
by convective mode of CRRT should be considered in
the setting of a large-volume of distribution intoxicant.
Convective mode CRRT can be considered in a patient
that cannot tolerate HD as initial treatment.
Questions
(Answers appear following the reference list)
1. Factor(s) that affect the benefit of RRT for the
treatment of drug overdose would include
a. the volume of distribution
b. the molecular weight
c. its protein binding
d. all of the above
2. If an intoxicant is highly protein bound, which of the





d. diffusive form of CRRT
3. If an intoxicant has low protein binding, a small
molecular weight and a low volume of distribution,





d. any of the above
4. Comparing the “dialysis bath” in RRT for AKI versus
RRT for intoxication in a child without AKI, the bath is
a. identical
b. should have physiologic levels of potassium and
phosphorous
5. Vancomycin removal is best achieved with either
intermittent high-efficiency HD or high-efficiency HD
followed by convective CRRT because vancomycin
a is highly protein bound
b. has a large volume of distribution
c. has a large molecular weight
d. all of the above
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